A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib

Clinical trial NCT05204628 · UNKNOWN

Trial details

NCT number: NCT05204628
Sponsor: Xuanzhu Biopharmaceutical Co., Ltd.
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2022-02-07
Primary completion: 2025-05-07
Enrollment: 238

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.